CAMBRIDGE, Mass.–(BUSINESS WIRE)–Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in the following January investor conferences:
- 40th Annual J.P. Morgan Healthcare Conference, to be held virtually, on Thursday, January 13th, 2022, at 9:45 a.m. ET, immediately followed by a Q&A session
- B. Riley Virtual Oncology Conference, on Friday, January 28th, 2022, at 11:00 a.m. ET
A live webcast of the presentations can be accessed through the Investors & Media section of Magenta’s website at https://investor.magentatx.com/events-and-presentations. A replay of each webcast will be available on Magenta’s website for 30 days following the events.
About Magenta Therapeutics
Magenta Therapeutics is a clinical-stage biotechnology company developing medicines designed to bring the curative power of stem cell transplants to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.
Magenta is based in Cambridge, Massachusetts. For more information, please visit www.magentatx.com.
Follow Magenta on Twitter: @magentatx.
Contacts
Leah Monteiro
Magenta Therapeutics
Vice President, Investor Relations
lmonteiro@magentatx.com